Open AccessJournal Article
Comparison of microtransplantation, chemotherapy and allogeneic transplantation in post-remission therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bo Cai,Qi-Yun Sun,Jian-Hui Qiao,Chang-Lin Yu,Kai-Xun Hu,Tie-Qiang Liu,Bingxia Li,Ya-Jing Huang,Yi Wang,Hong-Li Zuo,Zheng Dong,Yaqing Lei,Zhiqing Liu,Bo Yao,Caixia Li,Huisheng Ai,Mei Guo +16 more
5
TL;DR: The retrospectively summarized 45 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia and found that microtransplantation, MST may provide a favorable treatment for patients with Ph+ ALL.
read more
Abstract: Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Microtransplantation for myeloid sarcoma: Two case reports
TL;DR: In this article , two cases of myeloid sarcoma (MS) were treated by micro transplantation and the disease-free survival was 66 months and 55 months respectively.
4
Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients.
Minming Li,Chao Li,Chao Li,Suxia Geng,Xiaomei Chen,Ping Wu,Chengxin Deng,Xiaofang Chen,Zesheng Lu,Jianyu Weng,Jianyu Weng,Xin Du,Xin Du +12 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of human leukocyte antigen mismatched hematopoietic stem cell micro-transplantation (MST) in patients with MDS.
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.
Hui-Sheng Ai,Nelson J. Chao,David A. Rizzieri,Xiaojun Huang,Thomas R. Spitzer,Jianxiang Wang,Mei Guo,Armand Keating,Elizabeth F. Krakow,Didier Blaise,Jun Ma,Depei Wu,John L. Reagan,Usama Gergis,Rafael Duarte,Preety Chaudhary,Kai-Xun Hu,Chang-Lin Yu,Qi-Yun Sun,Ephraim J. Fuchs,B Cai,Ya-Jing Huang,Jia Qiao,David Gottlieb,Kirk R. Schultz,Mingyao Liu,Xiequn Chen,Wenming Chen,Jianmin Wang,Xiao-Hui Zhang,Jianyong Li,H. Huang,Zimin Sun,Fei Li,Linhua Yang,Lian-sheng Zhang,Lijuan Li,Kaiyan Liu,Jie Jin,Qifa Liu,Daihong Liu,Chun Ji Gao,Chuanbo Fan,Li Wei,Xi Zhang,Liangding Hu,Weijing Zhang,Yuyang Tian,Weidong Han,Jun-Ming Zhu,Zhijian Xiao,Daobin Zhou,Bolong Zhang,Yongqing Zhang,Xiaoxiong Wu,Xu-Liang Shen,Xuzhang Lu,Xinrong Zhan,Xiuli Sun,Yi Xiao,Jing Wang,Xiaoding Shi,Bo Zheng,Jie Chen,Banghe Ding,Zhao Wang,Fang Zhou,Meixiang Zhang,Yizhuo Zhang,Jie Sun,Bing Xia,Baoan Chen,Liang-Min Ma +72 more
TL;DR: In this paper , the International Microtransplant Interest Group provides recommendations and considerations for microtransplant in the treatment of elderly acute myeloid leukemia (EAML), and four major issues related to MST for treating EAML were addressed: therapeutic principle of MST, candidates for MST (1), induction chemotherapy regimens (3), and post-remission therapy based on MST.
2
Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia
B Cai,Yi Wang,Yangyang Lei,Yanping Shi,Qi-Yun Sun,Jian-Hui Qiao,Kai-Xun Hu,Yaqing Lei,Bing-Xia Li,Tie-Qiang Liu,Zhiqing Liu,Bo Yao,Xuecong Zhao,Xiaofei Li,Wen Zhao,Xiaoling Feng,Anli Xie,Xin Ning,Ming Feng,Weiwei Zhao,Jiayue Guo,Hui-Sheng Ai,Chang-Lin Yu,Mei Guo +23 more
TL;DR: Multivariate analyses demonstrated that white blood cells <30 × 109/L at diagnosis and sufficient hyper-CVAD cycles were prognostic factors for better 4-year OS and LFS, while the B-cell phenotype and higher number of infused CD34+ cells in the first cycle were predictors for favorable 4- year LFS.
Microtransplantation, an option to explore in hematological malignancies: A review article
Ali M Assiri
TL;DR: Improved overall survival and progression-free survival are shown, which suggest MT as a valid option to be investigated further in prospective controlled studies and could be explained by combined recipient-versus-tumor and graft-versus-tumor effects.
References
•Journal Article
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka,Daniel J. Weisdorf,Paul J. Martin,Hans G. Klingemann,Beatty P,Hows J,Thomas Ed +6 more
TL;DR: Reports of GVHD prevention trials should include an accurate description of the grading system used and should report actuarial rates of grades II-IV and III-IV GV HD corrected for graft failure and potential interventions for early relapse.
4.9K
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report
Madan Jagasia,Hildegard T. Greinix,Mukta Arora,Kirsten M. Williams,Daniel Wolff,Edward W. Cowen,Jeanne Palmer,Daniel J. Weisdorf,Nathaniel S. Treister,Guang-Shing Cheng,Holly Kerr,Pamela Stratton,Rafael F. Duarte,George B. McDonald,Yoshihiro Inamoto,Afonso Celso Vigorito,Sally Arai,Manuel B. Datiles,David A. Jacobsohn,Theo Heller,Carrie L. Kitko,Sandra A. Mitchell,Paul J. Martin,Howard M. Shulman,Roy S. Wu,Corey Cutler,Georgia B. Vogelsang,Stephanie J. Lee,Steven Z. Pavletic,Mary E.D. Flowers +29 more
TL;DR: The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence, and focuses attention on the causes of organ-specific abnormalities to chronic GVHD.
4.9K
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease
Madan Jagasia,Hildegard T. Greinix,Mukta Arora,Kirsten M. Williams,Daniel Wolff,Edward W. Cowen,Jeanne Palmer,Daniel J. Weisdorf,Nathaniel S. Treister,Guang-Shing Cheng,Holly Kerr,Pamela Stratton,Rafael F. Duarte,George B. McDonald,Yoshihiro Inamoto,Afonso Celso Vigorito,Sally Arai,Manuel B. Datiles,David A. Jacobsohn,Theo Heller,Carrie L. Kitko,Sandra A. Mitchell,Paul J. Martin,Howard M. Shulman,Roy S. Wu,Corey Cutler,Georgia B. Vogelsang,Stephanie J. Lee,Steven Z. Pavletic,Mary E.D. Flowers +29 more
TL;DR: In this article, the authors proposed a new clinical scoring system (0-3) that describes the extent and severity of chronic graft-versus-host disease for each organ or site at any given time, taking functional impact into account.
3.4K
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Hagop M Kantarjian,Susan O'Brien,Terry L. Smith,Jorge E. Cortes,Francis Giles,Miloslav Beran,Sherry Pierce,Yang O. Huh,Michael Andreeff,Charles A. Koller,Chul S. Ha,Michael J. Keating,Sharon B. Murphy,Emil J. Freireich +13 more
TL;DR: Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival.
783
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
Kirk R. Schultz,Andrew J. Carroll,Nyla A. Heerema,W P Bowman,Alexander Aledo,William B. Slayton,H N Sather,Meenakshi Devidas,H. W. Zheng,Stella M. Davies,Paul S. Gaynon,Michael E. Trigg,Robert Rutledge,Dean Thomas Jorstad,Naomi J. Winick,Michael J. Borowitz,Stephen P. Hunger,William L. Carroll,Bruce M. Camitta +18 more
TL;DR: Longer-term follow-up confirms the initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.
431
Related Papers (5)
Shinichi Kako,Fumihiko Hayakawa,Kiyotoshi Imai,Junji Tanaka,Shuichi Mizuta,Satoshi Nishiwaki,Heiwa Kanamori,Junichi Mukae,Yukiyasu Ozawa,Tadakazu Kondo,Takahiro Fukuda,Tatsuo Ichinohe,Shuichi Ota,Yoshinori Tanaka,Tohru Murayama,Shingo Kurahashi,Toru Sakura,Noriko Usui,Shigeki Ohtake,Hitoshi Kiyoi,Itaru Matsumura,Yasushi Miyazaki,Yoshiko Atsuta +22 more